A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Cáncer de los ovarios
No existen recomendaciones estándares para detectar el cáncer ovárico. El hecho de examinar a las mujeres con ecografías de la pelvis o exámenes de sangre, como el CA-125, no se ha comprobado que sea eficaz y tampoco se recomienda.
Las pruebas para BRCA se pueden hacer en mujeres en alto riesgo de cáncer ovárico.
La extirpación de los ovarios en mujeres que tengan una mutación en los genes BRCA1 y BRCA2 puede reducir el riesgo de sufrir cáncer de ovario, aunque este tipo de cáncer igualmente se puede presentar en otras áreas de la pelvis.
Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA. 2009;302:298-305.
National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Ovarian Cancer. 2009;v.2.
Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ. 2009;338:b249.
Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010 Sep;116(3):733-43.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.800.492.5538